| Literature DB >> 30367154 |
O B Myers1, V S Pankratz1, K C Norris2, J A Vassalotti3, M L Unruh1, C Argyropoulos4.
Abstract
Chronic Kidney Disease (CKD), is highly prevalent in the United States. Epidemiological systems for surveillance of CKD rely on data that are based solely on the NHANES survey, which does not include many patients with the most severe and less frequent forms of CKD. We investigated the feasibility of estimating CKD prevalence from the large-scale community disease detection Kidney Early Evaluation and Program (KEEP, n = 127,149). We adopted methodologies from the field of web surveys to address the self-selection bias inherent in KEEP. Primary outcomes studied were CKD Stage 3-5 (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2, and CKD Stage 4-5 (eGFR <30 mL/min/1.73 m2). The unweighted prevalence of Stage 4-5 CKD was higher in KEEP (1.00%, 95%CI: 0.94-1.05%) than in NHANES (0.51%, 95% CI: 0.43-0.59%). Application of a selection model that used variables related to demographics, recruitment and socio-economic factors resulted in estimates similar to NHANES (0.55%, 95% CI: 0.50-0.60%). Weighted prevalence of Stages 3-5 CKD in KEEP was 6.45% (95% CI: 5.70-7.28%) compared to 6.73% (95% CI: 6.30-7.19%) for NHANES. Application of methodologies that address the self-selection bias in the KEEP program may allow the use of this large, geographically diverse dataset for CKD surveillance.Entities:
Mesh:
Year: 2018 PMID: 30367154 PMCID: PMC6203800 DOI: 10.1038/s41598-018-34233-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1National Health and Nutrition Examination Survey (NHANES) and Kidney Early Evaluation Program (KEEP) participation in study.
Self-reported characteristics of NHANES reference population and KEEP participants without and with inverse probability weighting, 2001–2012.
| NHANES ( | KEEP ( | ||||
|---|---|---|---|---|---|
|
| Weighted % |
| Unweighted% | Weighted % | |
| Age | |||||
| 20–39 | 9,396 | 36.9 | 21,625 | 17.0 | 35.9 |
| 40–59 | 9,317 | 39.4 | 54,931 | 43.2 | 39.4 |
| 60–69 | 4,526 | 11.9 | 27,423 | 21.6 | 12.5 |
| 70+ | 5,278 | 11.8 | 23,170 | 18.2 | 12.2 |
| Female | 14,230 | 51.1 | 86,076 | 67.7 | 52.2 |
| Race/Ethnicity | |||||
| Mexican American/Other Hispanic | 7,116 | 12.8 | 16,275 | 12.8 | 14.9 |
| non-Hispanic White | 13,852 | 70.8 | 57,078 | 44.9 | 68.8 |
| non-Hispanic Black | 5,737 | 10.5 | 40,577 | 31.9 | 11.2 |
| Other | 1,812 | 5.9 | 13,219 | 10.4 | 5.2 |
| Diabetes | 3,736 | 9.6 | 36,309 | 28.6 | 8.5 |
| Hypertension | 9,777 | 29.7 | 69,813 | 54.9 | 31.6 |
| Chronic kidney disease | 731 | 2.0 | 5,562 | 4.4 | 1.7 |
| CHF/CAD/Stroke | 3,236 | 8.5 | 15,885 | 12.5 | 8.4 |
| Diabetes family history | 12,162 | 40.8 | 71,001 | 55.8 | 44.0 |
| Heart attack family history | 3,599 | 13.8 | 43,885 | 34.5 | 13.3 |
| Weight status | |||||
| Overweight | 9,782 | 33.9 | 41,409 | 32.6 | 36.6 |
| Obese | 9,783 | 32.9 | 46,480 | 36.6 | 35.8 |
| Smoking status | |||||
| Smoker | 6,313 | 22.8 | 13,145 | 10.3 | 22.1 |
| Former smoker | 7,248 | 24.8 | 32,981 | 25.9 | 25.0 |
| Insurance | |||||
| None reported | 6,534 | 19.3 | 27,816 | 21.9 | 18.3 |
| Insured | 19,773 | 75.5 | 91,718 | 72.1 | 76.9 |
| Medicaid | 2,210 | 5.2 | 7,615 | 6.0 | 4.9 |
| Education | |||||
| Less than high school or GED | 8,080 | 18.4 | 19,642 | 15.4 | 18.9 |
| High school or GED | 6,684 | 24.1 | 32,702 | 25.7 | 22.9 |
| Greater than school graduate | 13,753 | 57.5 | 74,805 | 58.8 | 58.2 |
CHF/CAD/stroke – congestive heart failure/coronary artery disease or stroke; CKD – chronic kidney disease; KEEP – Kidney Early Evaluation Program; NHANES - National Health and Nutrition Examination Survey.
CKD prevalence estimated from NHANES and from KEEP without and with inverse probability weighting, 2001–2012.
| Measure | NHANES ( | KEEP ( | |||||
|---|---|---|---|---|---|---|---|
|
| Weighted |
| Unweighted | Unweighted-GEE | Weighted | Weighted-GEE | |
| % | % | % | % | % | |||
| CKD Stage 3 | 2,453 | 6.23 (5.82–6.66) | 16,706 | 13.14 (12.95–13.33) | 12.83 (11.88–13.85) | 8.57 (8.30–8.85) | 6.45 (5.70–7.28) |
| CKD Stage 3-5 | 2,692 | 6.73 (6.30–7.19) | 17,973 | 14.14 (13.94–14.33) | 13.86 (12.88–14.90) | 9.14 (8.86–9.43) | 6.90 (6.12–7.78) |
| CKD Stage 4-5 | 239 | 0.51 (0.43–0.59) | 1,267 | 1.00 (0.94–1.05) | 1.01 (0.93–1.09) | 0.55 (0.50–0.60) | 0.52 (0.42–0.64) |
Weighted estimates accounted for NHANES sampling design or self-selection by KEEP. KEEP GEE estimates accounted for participant clustering within regional affiliates. CKD – chronic kidney disease; KEEP – Kidney Early Evaluation Program; NHANES - National Health and Nutrition Examination Survey.
Figure 2Prevalence of CKD Stage 3 and Stage 4-5 by year screened for KEEP and NHANES. (KEEP – Kidney Early Evaluation Program; NHANES - National Health and Nutrition Examination Survey).
Prevalence of albuminuria (ACR 30–300 mg/g and ACR > 300 mg/g) estimated from NHANES and from KEEP without and with inverse probability weighting, 2003–2012.
| Measure | NHANES ( | KEEP ( | |||||
|---|---|---|---|---|---|---|---|
|
| Weighted |
| Unweighted | Unweighted-GEE | Weighted | Weighted-GEE | |
| % | % | % | % | % | |||
| ACR 30–300 mg/g | 2,498 | 5.33 (5.03–5.65) | 11,663 | 10.29 (10.11–10.47) | 10.47 (10.00–10.95) | 7.14 (6.86–7.43) | 6.20 (5.61–6.85) |
| ACR > 300 mg/g | 472 | 0.86 (0.77–0.96) | 1,425 | 1.26 (1.19–1.32) | 1.33 (1.20–1.47) | 0.62 (0.55–0.70) | 0.54 (0.45–0.66) |
Weighted estimates accounted for NHANES sampling design or self-selection by KEEP. KEEP GEE estimates accounted for participant clustering within regional affiliates. ACR – urinary albumin-creatinine ratio; CKD – chronic kidney disease; KEEP – Kidney Early Evaluation Program; NHANES – National Health and Nutrition Examination Survey.
Figure 3Prevalence (%) of CKD Stage 3 and Stage 4-5 by year screened for KEEP and NHANES. (KEEP – Kidney Early Evaluation Program; NHANES - National Health and Nutrition Examination Survey).